
Home » Adimab, Celgene collaborate for antibody discovery
Adimab, Celgene collaborate for antibody discovery
August 21, 2013
Adimab, a technology company focuses on the discovery of fully human antibodies, has announced a multi-target discovery collaboration with Celgene of Summit, NJ. Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets. Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.
Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets. For each target, the agreement grants Celgene the right to research antibodies generated during the collaboration for potential use as therapeutic products. Adimab will receive an undisclosed upfront payment. In addition, for each target, Celgene will have the option to exclusively license antibodies generated during the collaboration. If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales.
"The speed and technical superiority of our platform drives all of our deal flow," said Guy Van Meter, vice president of business development at Adimab. "The Adimab Platform is an extremely versatile antibody discovery and engineering tool that can be applied to a variety of different therapeutic development approaches, including IgG discovery, optimization, humanization and bispecifics."
Upcoming Events
-
05Dec
-
14Apr